A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases | MicrobiomeTrials← Back to trialsNCT07049081
A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases
TERMINATEDPHASE1INTERVENTIONAL
Trial Details
Start: 2025-07-17Est. Completion: 2026-03-20
Enrollment target: 3 participants Locations- The Third The People's Hospital of Bengbu, Bengbu, Anhui, China
- The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
- The second Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shanxi, China
Other microbiome trials you might be interested in
Systemic Lupus ErythematosusLupus Nephritis
Systemic lupus erythematosus (SLE) is the most common systemic autoimmune disease in China. The kidneys are the organ mo…
Nanjing, ChinaCompleted Jan 2028
Relapsed/Refractory Autoimmune Diseases
This study is a single-center, single-arm, open-label, investigator-initiated early exploratory clinical trial designed …
Multiple LocationsEst. completion Jul 30, 2027
Recruiting
Autoimmune Hemolytic Anemia (AIHA)
1. wAIHA Treatment Regimen: Group A (50mg group): Orelabrutinib 50 mg, orally, once daily. After 4 weeks of treatment, i…
Beijing, ChinaEst. completion Mar 1, 2027